RGX-104 (Synonyms: Abequolixron hydrochloride) |
| Katalog-Nr.GC19448 |
RGX-104 ist ein niedermolekularer LXR-Agonist, der die angeborene ImmunitÄt durch transkriptionelle Aktivierung des ApoE-Gens moduliert.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 610318-03-1
Sample solution is provided at 25 µL, 10mM.
RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
Oral administration of GW3965 or RGX-104 to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Strong tumor growth suppression is also observed in animals bearing large tumors. In some instances, the treatment causes partial or complete tumor regression. Responses are seen across a wide spectrum of malignancies, including lung cancer, melanoma, glioblastoma, and ovarian, renal cell, triple-negative breast, and colon cancer[1].
[1]. Tavazoie MF, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Feb 8;172(4):825-840.e18.
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *